Search

Table S1. Prevalence by age and sex, alternative validation strategy, 2010, AOK data. Table S2. Incidence rate by age and sex, alternative validation strategy, 2011–2013, AOK data. Table S3. Results of the complete Cox-regression model, risk of incidence of POAG, 2011-2013, AOK data. Table S4. Results of the complete Cox-regression model, risk of incidence of POAG, alternative validation strategy, 2011-2013, AOK data. Table S5. Results of the complete Cox-regression model, risk of incidence of POAG, persons with diabetes excluded, 2011–2013, AOK data. Table S6. Results of the complete Cox-regression model, risk of incidence of POAG, persons with (prior or later) primary angle-closure glaucoma (H40.2) and secondary glaucoma (H40.3–6) excluded, 2011–2013, AOK data. (DOCX 1680 kb)

Table of confidence intervals for baseline demographic characteristics (age, gender, time since diagnosis, baseline visual acuity) in the indication diabetic macular oedema: results for the OCEAN study and for selected randomized controlled trials. (DOCX 20Â kb)

Table of confidence intervals for baseline demographic characteristics of OCEAN patients, by indication. (DOCX 14Â kb)

Table of confidence intervals for baseline demographic characteristics (age, gender, time since diagnosis, baseline visual acuity) in the indication neovascular age-related macular degeneration: results for the OCEAN study and for selected randomized controlled trials. (DOCX 25Â kb)

Table of confidence intervals for additional baseline demographic parameters (BMI, diabetes type, HbA1c) in the indication diabetic macular oedema: results for the OCEAN study and for selected randomized controlled trials. (DOCX 18Â kb)

Table of confidence intervals for baseline demographic characteristics (age, gender, time since diagnosis, baseline visual acuity) in the indication neovascular age-related macular degeneration: results for the OCEAN study and for selected randomized controlled trials. (DOCX 25Â kb)

Table of selected randomized controlled trials for comparison to OCEAN, by indication. (DOCX 15Â kb)

Table of confidence intervals for baseline demographic characteristics (age, gender, time since diagnosis, baseline visual acuity) in the indication diabetic macular oedema: results for the OCEAN study and for selected randomized controlled trials. (DOCX 20Â kb)

Table of confidence intervals for baseline demographic characteristics (age, gender, time since diagnosis, baseline visual acuity) in the indications branch and central retinal vein occlusion: results for the OCEAN study and for selected randomized controlled trials. (DOCX 20Â kb)

Table of confidence intervals for baseline demographic characteristics (age, gender, time since diagnosis, baseline visual acuity) in the indications branch and central retinal vein occlusion: results for the OCEAN study and for selected randomized controlled trials. (DOCX 20Â kb)

Table of confidence intervals for medical history parameters in the indication neovascular age-related macular degeneration: results for the OCEAN study and for those selected randomized controlled trials for which comparable data were available. (DOCX 15Â kb)

Table of confidence intervals for additional baseline demographic parameters (BMI, diabetes type, HbA1c) in the indication diabetic macular oedema: results for the OCEAN study and for selected randomized controlled trials. (DOCX 18Â kb)